"Azabicyclo Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS.
| Descriptor ID |
D053961
|
| MeSH Number(s) |
D02.145.074 D03.605.084.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azabicyclo Compounds".
Below are MeSH descriptors whose meaning is more specific than "Azabicyclo Compounds".
This graph shows the total number of publications written about "Azabicyclo Compounds" by people in this website by year, and whether "Azabicyclo Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 0 | 1 |
| 2026 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azabicyclo Compounds" by people in Profiles.
-
Standardized numbering and alignment of the KPC family of ?-lactamases. Antimicrob Agents Chemother. 2026 Jul; 70(7):e0186825.
-
Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers. Antimicrob Agents Chemother. 2026 Jun 03; 70(6):e0026826.
-
Reduced catalytic activity of KPC ?-lactamase can increase ceftazidime resistance. Commun Biol. 2026 Apr 07; 9(1).
-
Pharmacokinetics of sulbactam-durlobactam in patients with Acinetobacter baumannii ventriculitis: a report of two cases. Antimicrob Agents Chemother. 2025 11 05; 69(11):e0067425.
-
Bacteriophage treatment is effective against carbapenem-resistant Klebsiella pneumoniae (KPC) in a neutropenic murine model of gastrointestinal translocation and renal infection. Antimicrob Agents Chemother. 2025 02 13; 69(2):e0091924.
-
Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2025 May; 25(5):574-584.
-
In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 09; 38:252-255.
-
The mechanism of ceftazidime and cefiderocol hydrolysis by D179Y variants of KPC carbapenemases is similar and involves the formation of a long-lived covalent intermediate. Antimicrob Agents Chemother. 2024 03 06; 68(3):e0110823.
-
Klebsiella pneumoniae carbapenemase variant 44 acquires ceftazidime-avibactam resistance by altering the conformation of active-site loops. J Biol Chem. 2024 01; 300(1):105493.
-
Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Clin Infect Dis. 2023 07 26; 77(2):186-193.